IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
Abstract Background Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of...
Saved in:
Main Authors: | N. Vergis, V. Patel, K. Bogdanowicz, J. Czyzewska-Khan, F. Fiorentino, E. Day, M. Cross, N. Foster, E. Lord, R. Goldin, E. Forrest, M. Thursz |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f45e5e1c18fb4154a6fd28e5c0c832cd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever
by: Tolga Yildirim, et al.
Published: (2021) -
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
by: Kacar M, et al.
Published: (2020) -
Muckle–Wells syndrome: clinical perspectives
by: Tran TA
Published: (2017) -
Severe alcoholic hepatitis: current perspectives
by: Philips CA, et al.
Published: (2019) -
Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis
by: Mengfei Liu, et al.
Published: (2021)